EUR 18,30
Währung umrechnenAnzahl: 1 verfügbar
In den WarenkorbZustand: Good. Good condition. A copy that has been read but remains intact. May contain markings such as bookplates, stamps, limited notes and highlighting, or a few light stains.
EUR 7,27
Währung umrechnenAnzahl: 1 verfügbar
In den WarenkorbZustand: Good. This is an ex-library book and may have the usual library/used-book markings inside.This book has hardback covers. In good all round condition. Please note the Image in this listing is a stock photo and may not match the covers of the actual item,2050grams, ISBN:9780123695215.
EUR 58,63
Währung umrechnenAnzahl: 1 verfügbar
In den WarenkorbZustand: Used.
Anbieter: Ria Christie Collections, Uxbridge, Vereinigtes Königreich
EUR 61,89
Währung umrechnenAnzahl: Mehr als 20 verfügbar
In den WarenkorbZustand: New. In.
Anbieter: AHA-BUCH GmbH, Einbeck, Deutschland
EUR 59,97
Währung umrechnenAnzahl: 1 verfügbar
In den WarenkorbTaschenbuch. Zustand: Neu. Druck auf Anfrage Neuware - Printed after ordering - The idea for convening a Fourth International Symposium on Platinum Coordination Complexes in Cancer Chemotherapy was born in an assembly of researchers from the Vermont Regional Cancer Center and the Norris Cotton Cancer Center who shared a common interest in metal complexes. It was agreed by those assembled that sufficient time had passed since the Third International Symposium on Platinum Coor dination Complexes in Cancer Chemotherapy held in 1976 at the Wadley Institutes of Molecular Medicine in Dallas, Texas, during which several advances in the chemistry, biochemistry, pharmacology and clinical use of platinum complexes had occurred, to warrant a fourth symposium. Furthermore, intensive investigations in progress were bringing sophisticated methodologies to bear on the problems in the field, clinical trials were yielding interesting results, and unique approaches to cancer therapy were being designed. Therefore, an organizing committee was formed and planning culminated in the symposium which was held in Burlington, Vermont, June 22-24, 1983.
Anbieter: Ria Christie Collections, Uxbridge, Vereinigtes Königreich
EUR 169,56
Währung umrechnenAnzahl: Mehr als 20 verfügbar
In den WarenkorbZustand: New. In.
Anbieter: Ria Christie Collections, Uxbridge, Vereinigtes Königreich
EUR 169,56
Währung umrechnenAnzahl: Mehr als 20 verfügbar
In den WarenkorbZustand: New. In.
Anbieter: AHA-BUCH GmbH, Einbeck, Deutschland
EUR 156,28
Währung umrechnenAnzahl: 1 verfügbar
In den WarenkorbTaschenbuch. Zustand: Neu. Druck auf Anfrage Neuware - Printed after ordering - The addition of chemotherapy as an effective means to treat cancer has had a major impact on selected human malignancies. Due to a general inability to dif ferentiate between normal and neoplastic cells, little selectivity exists in currently used oncolytic drugs. Consequently, significant toxicity to the patient is expected when systemic cancer chemotherapy is chosen as an appropriate therapeutic in tervention. Much of this toxicity, such as damage to the bone marrow, gastroin testinal tract, or hair follicles, is predictable based upon the fact that anticancer drugs kill actively dividing cells. These types of toxicities, while serious, are usually manageable and reversible and are, therefore, not often considered to be dose limiting. Unfortunately, several of the most important anticancer drugs also damage tissues in which the growth fraction is relatively small. Such toxicities can not be predicted based on the chemical structure of the drugs, are often not detected in preclinical studies, and are encountered frequently for the first time in clinical studies. Further, unlike most of the proliferative-dependent toxicities, the unpre dicted toxicities are usually irreversible or only partially reversible upon cessation of drug administration. Because of this, the unpredicted toxicities are referred to as dose limiting. They represent a significant barrier to the ultimate efficacy of several of our most important anticancer drugs.
Anbieter: AHA-BUCH GmbH, Einbeck, Deutschland
EUR 164,49
Währung umrechnenAnzahl: 1 verfügbar
In den WarenkorbBuch. Zustand: Neu. Druck auf Anfrage Neuware - Printed after ordering - The addition of chemotherapy as an effective means to treat cancer has had a major impact on selected human malignancies. Due to a general inability to dif ferentiate between normal and neoplastic cells, little selectivity exists in currently used oncolytic drugs. Consequently, significant toxicity to the patient is expected when systemic cancer chemotherapy is chosen as an appropriate therapeutic in tervention. Much of this toxicity, such as damage to the bone marrow, gastroin testinal tract, or hair follicles, is predictable based upon the fact that anticancer drugs kill actively dividing cells. These types of toxicities, while serious, are usually manageable and reversible and are, therefore, not often considered to be dose limiting. Unfortunately, several of the most important anticancer drugs also damage tissues in which the growth fraction is relatively small. Such toxicities can not be predicted based on the chemical structure of the drugs, are often not detected in preclinical studies, and are encountered frequently for the first time in clinical studies. Further, unlike most of the proliferative-dependent toxicities, the unpre dicted toxicities are usually irreversible or only partially reversible upon cessation of drug administration. Because of this, the unpredicted toxicities are referred to as dose limiting. They represent a significant barrier to the ultimate efficacy of several of our most important anticancer drugs.